Use of the Methoxyflurane as Pain-killer in the Prehospital Management of Acute Myocardial Infarction

NCT07445737 · tracked via the Priya Life Science France tracker

Sponsor

Assistance Publique - Hôpitaux de Paris

Phase

Phase 3

Started

2026-06

Last updated

2026-03-03

Condition(s) studied

STEMI - ST Elevation Myocardial Infarction

Investigational drug(s) / intervention(s)

Methoxyflurane →Morphine →

Methoxyflurane: Patient's self-administration of methoxyflurane (Penthrox®) with dedicated inhaler Initial dose: 3 mL (1 vial). A second 3 mL dose can be used. Treatment: from inclusion to hospital arrival.

Morphine: Morphine intra-venous infusion: 3 mg bolus repeated every 5 minutes until obtaining VAS ≤ 3. Treatment: from inclusion to hospital arrival

Study summary

* Chest pain is the main symptom of acute myocardial infarction. A precocious analgesic treatment is justified by patient's comfort and unfavorable hemodynamic consequences of persistent pain. Morphine is the painkiller historically prescribed in this situation. Morphine has never been evaluated vs placebo and is strongly suspected to decrease oral anti-platelet efficacy. Then, morphine has been downgraded, in the 2017 European guidelines (European Society of Cardiology - ESC) from I to IIa. To find alternative treatment is required.
* The methoxyflurane is an anesthetic gas used in emergency setting for about twenty years. It is now commonly used in France. Its analgesic properties have been demonstrated. Its main advantages are its maneuverability as it is delivered by inhalation, i.e. without (before) any venous access and self-administered by the patient. Tolerability is good. It could be an excellent alternative to morphine.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Patient age ≥ 18 years * Patient managed in pre-hospital setting for a ST elevation myocardial infarction (STEMI) : Chest pain \< 12 hours with moderate to severe pain (VAS \> 6/10) or STEMI on ECG according to 2017 ESC guidelines Exclusion Criteria: * Previous analgesic treatment for this episode of chest pain * Hypersensitivity to morphine, methoxyflurane, any fluorinated anesthetic or any of the excipients listed in SmPC, * Decompensated respiratory failure (in the absence of artificial ventilation), * Severe hepatocellular insufficiency (with encephalopathy), * Acute head trauma and intracranial hypertension in the absence of controlled ventilation, * Uncontrolled epilepsy, * Treatment with buprenorphine, nalbuphine and pentazocine, naltrexone, nalmefene or sodium oxybate, * Breastfeeding, in case of initiation or continuation after birth of a long-term treatment. * Known malignant hyperthermia or genetic predisposition of the patient. * History of serious adverse effects of the patient or his family after administration of inhaled anesthetics. * History of signs of liver damage after use of methoxyflurane or after anesthesia with a halogenated hydrocarbon. * Clinically significant renal impairment. * Known renal failure with creatinine clearance below 30 ml/min or undergoing extracorporeal renal replacement therapy. * Altered level of consciousness due to any cause, including head trauma, drug or alcohol use. * Clinical evidence of cardiovascular instability (PAS \<90 mm Hg). * Clinical evidence of respiratory depression. * Incapacity to self-assess pain intensity * Incapacity to methoxyflurane self-administration * Known pregnancy, breastfeeding, minors or incapacity (curatorship or guardianship) * Participation in another interventional study involving human participants or being in the exclusion period at the end of a previous study involving human participants * Absence of a Social Security

Primary outcome measure(s)

Demonstrate that methoxyflurane self-administered by the patient is at least as efficient in achieving pain relief that morphine — at 30 minutes
To demonstrate that methoxyflurane self-administered by the patient suffering chest pain related to an acute myocardial infarction is at least as efficient in achieving pain relief that morphine with better tolerance (achieving pain relief, i.e. pain intensity score on visual analogic scale (VAS) ≤ 3 at 30 minutes)

Trial sites (1)

Facility	City	Region	Status
Hôpital Avicenne	Bobigny	France

More Assistance Publique - Hôpitaux de Paris trials in France

Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases Recruiting

VExUS in Ards Patients and Association with AKI Recruiting

Periodontitis and Inflammation: Study on Biological Samples Recruiting

Kinematic Analysis of Latissimus Dorsi Transfer Results for Shoulder External Rotation Resuscitation Starting soon

Creation of a Biological Collection for Medical Research Purposes for Patients at the Reference Center for Rare Diseases of the Blood Vessels of the Brain and Eye at Lariboisière Hospital Active, not recruiting

Other trials for the same condition

Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07445737 on ClinicalTrials.gov ↗ ← All trials in France